Lumenis, the inventor of intense pulsed light (IPL), presents the first and only IPL that is approved by the United States Food and Drug Administration and listed by the Therapeutic Goods Administration for the management of dry eye disease due to meibomian gland dysfunction.
OptiLight elevates dry eye management with Lumenis’ patented optimal pulse technology (OPT) and user-centered design. Get the safe, precise, elegant procedure you want and the comfortable, effective therapy your patients need to manage dry eye disease with OptiLight.
Contact: Lumenis (AUS) 1800 586 364 or (NZ) 0800 239 015
